1. HBW Insight
  2. >>Geography
  3. >>North America
  4. >>United States

More Problems With Lead In Supplements: Health And Wellness Industry News Roundup

Another recall by Chicago firm Ton Shen Health; Mannatech rides Asia-Pacific growth; and more news in brief.

For the second time in three months Chicago firm Ton Shen Health is recalling a supplement product due to elevated levels of lead above the acceptable level for children. FDA said in a Nov. 7 consumer advisory that the firm's Life Rising brand "Side Head Regulator TT" tablets tested positive for elevated lead levels and the firm, due to the possibility of use by children, is recalling the product. The recalled tablets, distributed in a 1.6-ounce white plastic package, mostly were sold locally in Chicago area retail stores, though some were distributed to other states through mail orders. The firm in August recalled its Life Rising DHZC-2 supplement and FDA, state and local officials investigated two deaths potentially linked to use of the product. (Also see "FDA Investigates Lead-Containing Supplement: Health And Wellness Industry Roundup" - HBW Insight, 1 September, 2016.) FDA also in 2016 has investigated lead poisoning linked to Bentonite Me Baby medicinal clay made by Alikay Naturals after receiving an advisory from Minnesota officials. ([A#PS108142])

Nutritional supplement direct seller [Mannatech Inc.]'s third-quarter net income reached $1.3m, 46 cents per diluted share, with operations outside of the Americas accounting for approximately 60.5% of its consolidated net sales. The Coppell, Texas-based firm 's Nov. 8 earnings release stated that operating expenses were more than $4m higher than in the year-ago period, when it also incurred more than $2.1m in other expenses as its net income was reported at $68,000. Net sales for the July-September period grew 9.8% to $48.1m with Asia/Pacific net sales up 15.9% to $25.5m. Mannatech said product launches and promotions increased Asia/Pacific net sales by $2.9m and its loyalty program spurred a $400,000 increase

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

Some Laid Off Employees Called Back At US FDA

 
• By Sarah Karlin-Smith

Some FDA employees who were recently laid off by the Trump Administration are being called back to work, multiple sources confirmed to the Pink Sheet.

US Proposal To Remove Phenylephrine From OTC Monograph Could Stress-Test Streamlined Process

 
• By Malcolm Spicer

Proposed administrative order likely is first to prompt opposition from OTC industry or other stakeholders potentially delaying or deferring the agency’s expectation for moving its proposal to a deemed final order effective one year after it would be published.

FDA Clears Qnovia’s NRT Inhalation IND, Commits To ‘Stimulating’ Smoking Cessation Innovation

 
• By Malcolm Spicer

Qnovia notes NRT inhalation product recently received investigational new drug clearance from FDA as agency and NIH say innovation needed smoking cessation to help improve rate of success for quitting the habit that kills around 500,000 US consumers annually.

Washington State TFCA Violators Likely To Face Conversation Before Penalties – DOE

 
• By Eileen Francis

The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”

More from North America

Washington State TFCA Violators Likely To Face Conversation Before Penalties – DOE

 
• By Eileen Francis

The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”

Adcomm Reform: Getting Needed Information More Important Than Vote Or Discussion

 
• By Derrick Gingery

US FDA Office of New Drugs Director Peter Stein says review divisions have made the case that a discussion-only meeting would solicit the necessary input.

US FDA’s Petition Procedures No Place For OTC Acetaminophen Pediatric Dosing Enforcement

 
• By Malcolm Spicer

Requests for “enforcement actions are not within the scope of FDA’s citizen petition procedures,” CDER says, rejecting petition dosing device firm Parenteral Technologies submitted as it prepares for workshop on Pediatric Research Equity Act requirements for OTC NDA sponsors.